Kevin McBride

Investor

General Partner and Chief Scientific Officer at AmorChem

About

Kevin McBride is General Partner and CSO of AmorChem, where he provides scientific oversight for the AmorChem II portfolio and serves as acting CEO of ARNA Therapeutics. He joined AmorChem in 2013 as Director of Project Management before becoming Vice President, Research, and previously spent 25 years in university research and the biotechnology industry, helping create and lead R&D at companies including Compatigène and Chronogen. He holds an MSc in analytical chemistry from Queen's University, Belfast, a PhD in biochemistry from the University of London School of Pharmacy, and completed postdoctoral work at the Institut de recherches cliniques de Montréal.